U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25ClN2OS
Molecular Weight 400.965
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZUCLOPENTHIXOL

SMILES

OCCN1CCN(CC\C=C2/C3=CC(Cl)=CC=C3SC4=C2C=CC=C4)CC1

InChI

InChIKey=WFPIAZLQTJBIFN-DVZOWYKESA-N
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-

HIDE SMILES / InChI
Molecular Formula C22H25ClN2OS
Molecular Weight 400.965
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2 receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Antagonist
2849
Antagonist
2849
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CLOPIXOL

Approved Use

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
Primary
Approved
8583
CLOPIXOL

Approved Use

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 day
OTHER
https://www.medicines.org.uk/emc/product/994/smpc#PHARMACOKINETIC_PROPS
ZUCLOPENTHIXOL serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
OTHER
https://www.medicines.org.uk/emc/product/993/smpc#PHARMACOKINETIC_PROPS
ZUCLOPENTHIXOL unknown
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / 2 days multiple, oral
Recommended
Dose: 100 mg, 1 times / 2 days
Route: oral
Route: multiple
Dose: 100 mg, 1 times / 2 days
Sources:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
Disc. AE: Neuroleptic malignant syndrome...
AEs leading to
discontinuation/dose reduction:
Neuroleptic malignant syndrome
Sources:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
600 mg 1 times / 4 weeks multiple, intramuscular
Recommended
Dose: 600 mg, 1 times / 4 weeks
Route: intramuscular
Route: multiple
Dose: 600 mg, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/1681680/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/1681680/
Sources:
https://pubmed.ncbi.nlm.nih.gov/1681680/
AEs

AEs

AESignificanceDosePopulation
Neuroleptic malignant syndrome Disc. AE
100 mg 1 times / 2 days multiple, oral
Recommended
Dose: 100 mg, 1 times / 2 days
Route: oral
Route: multiple
Dose: 100 mg, 1 times / 2 days
Sources:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
PubMed

PubMed

TitleDatePubMed
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
1987 Jul
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
2012 Apr 18
Patents

Patents

US20080139573
9
WO/2008/069726A1
7

Sample Use Guides

In Vivo Use Guide
Clopixol tablets: The usual dose is 10 to 50 mg per day. Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as instructed by your doctor. Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:17:17 GMT 2025
Edited
by admin
on Mon Mar 31 18:17:17 GMT 2025
Record UNII
47ISU063SG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZUCLOPENTHIXOL
INN   MART.   WHO-DD  
INN  
Official Name English
CLOPIXOL
Preferred Name English
CLOPENTHIXOL CIS(Z)-FORM [MI]
Common Name English
zuclopenthixol [INN]
Common Name English
ZOCLOPENTHIXOL
Common Name English
CLOPENTHIXOL CIS(Z)-FORM
MI  
Common Name English
Zuclopenthixol [WHO-DD]
Common Name English
ZUCLOPENTHIXOL [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AF05
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
WHO-VATC QN05AF05
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
NCI_THESAURUS C29710
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
Code System Code Type Description
LACTMED
Zuclopenthixol
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
NCI_THESAURUS
C66713
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
MERCK INDEX
m3653
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY Merck Index
PUBCHEM
5311507
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
CHEBI
51364
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
WIKIPEDIA
ZUCLOPENTHIXOL
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
EVMPD
SUB00195MIG
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
258-758-5
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
DRUG CENTRAL
2877
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
RXCUI
114176
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL87385
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
DRUG BANK
DB01624
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
INN
5443
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID3048233
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
FDA UNII
47ISU063SG
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
IUPHAR
7559
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
SMS_ID
100000078802
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
CAS
53772-83-1
Created by admin on Mon Mar 31 18:17:17 GMT 2025 , Edited by admin on Mon Mar 31 18:17:17 GMT 2025
PRIMARY
Related Record Type Details
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY H MEMBER 2
OFF-TARGET->INHIBITOR
IC50
D(1A) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
Structure of ZUCLOPENTHIXOL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
D(2) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
MAJOR
ALPHA-1A ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
Related Record Type Details
Structure of ZUCLOPENTHIXOL ACETATE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of ZUCLOPENTHIXOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966